Table 4. Invasive tumour characteristic for patients who underwent surgery (excluding 16 patients with ductal carcinoma in situ).
| Bradford (n=24) | Huddersfield and Calderdale (n=52) | Leeds (n=67) | York (n=43) | Total (n=186) | ||
| Grade | 1 | 1 | 6 | 6 | 3 | 16 (9%) |
| 2 | 12 | 34 | 37 | 16 | 99 (53%) | |
| 3 | 11 | 11 | 22 | 22 | 66 (35%) | |
| Not stated | 0 | 1 | 2 | 2 | 5 (3%) | |
| Oestrogen receptor positive | 17 (71%) | 39 (75%) | 52 (78%) | 29 (67%) | 137 (74%) | |
| HER2 positive | 3 (13%) | 11 (21%) | 19 (28%) | 7 (16%) | 40 (22%) | |
| Triple receptor negative | 7 (29%) | 10 (19%) | 9 (13%) | 10 (23%) | 36 (19%) | |
| Post-menopausal, oestrogen receptor positive | 13 (54%) | 30 (58%) | 34 (51%) | 25 (58%) | 102 (55%) | |
| Post neoadjuvant chemotherapy | 6 | 5 | 11 | 5 | 27 (14%) | |
| Maximum size on pre-operative imaging | <2 cm | 9 | 25 | 29 | 14 | 77 (41%) |
| >2 cm | 15 | 27 | 36 | 22 | 100 (54%) | |
| Not stated | 0 | 0 | 2 | 7 | 9 (5%) | |